- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Vyome Holdings, Inc.(HIND)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HIND
11/13/2026: HIND (1-star) is currently NOT-A-BUY. Pass it for now.
Vyome Holdings, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing novel therapeutics for immuno-inflammatory and rare diseases. The company's main strengths lie in its specialized pipeline candidates, such as VT-1953 and VT-1908, and an asset-light operating model that leverages cross-border research capabilities. Its primary investment story centers on the potential clinical success and out-licensing of these novel topical programs in high-value therapeutic markets. However, the company faces significant execution risks, including micro-cap price volatility, ongoing operating losses, and heavy reliance on external capital. This stock best suits high-risk growth investors willing to monitor clinical trial milestones, regulatory updates, and cash burn metrics closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company lacks consistent revenue scaling, though high-risk growth seekers look at its early-stage clinical pipeline. |
| Momentum investor | Strong fit while signal remains positive | Low float and clinical catalysts can occasionally trigger sharp short-term price movements. |
| Value investor | Weak fit | Ongoing operating losses and lack of earnings make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for clinical development. |
| Low-risk investor | Weak fit | High clinical uncertainty, micro-cap volatility, and cash burn present substantial risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Low trading volumes and micro-cap status result in sharp intraday and periodic price swings. |
| Valuation risk | High | Valuation is driven by speculative clinical potential rather than trailing earnings or book value. |
| Competition risk (biotech and pharmaceutical development) | High | Well-funded competitors can out-market or out-develop smaller clinical-stage biotechs. |
| Business quality | Medium / high | The firm holds promising science and patents, but lacks established commercial depth. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Clinical trial success, regulatory approvals, and capital raising must be executed flawlessly to survive. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.09M USD | Price to earnings Ratio 0.89 | 1Y Target Price 8.83 |
Price to earnings Ratio 0.89 | 1Y Target Price 8.83 | ||
Volume (30-day avg) 11.4K shares | Beta - | 52 Weeks Range 1.53 - 5.88 | Updated Date 11/15/2026 |
52 Weeks Range 1.53 - 5.88 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.78 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -34.09% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Pharmaceutical Products & Licensing | Legacy commercialized anti-fungal products and associated royalty or licensing agreements primarily in regional markets. | This segment provides minor baseline revenue, but the core investment case rests on the biotechnology pipeline. |
| Biotechnology R&D Pipeline | Future potential commercial milestones, out-licensing fees, and product sales from clinical candidates like VT-1953 and VT-1908. | This segment currently generates no direct commercial product sales and operates as a capital investment center. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 0.89 | Forward PE - | Enterprise Value 3.24M | Price to Sales(TTM) 72.43 |
Enterprise Value 3.24M | Price to Sales(TTM) 72.43 | ||
Enterprise Value to Revenue 24.94 | Enterprise Value to EBITDA - | Shares Outstanding 7.02M | Shares Floating 3.65M |
Shares Outstanding 7.02M | Shares Floating 3.65M | ||
Percent Insiders 52.89 | Percent Institutions 2.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

